Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Arcus Biosciences (RCUS) Shares Outstanding (Diluted Average): 2021-2025

Historic Shares Outstanding (Diluted Average) for Arcus Biosciences (RCUS) over the last 4 years, with Sep 2025 value amounting to $106.5 million.

  • Arcus Biosciences' Shares Outstanding (Diluted Average) rose 16.52% to $106.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.5 million, marking a year-over-year increase of 16.52%. This contributed to the annual value of $90.1 million for FY2024, which is 21.76% up from last year.
  • As of Q3 2025, Arcus Biosciences' Shares Outstanding (Diluted Average) stood at $106.5 million, which was down 0.00% from $106.5 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Shares Outstanding (Diluted Average) registered a high of $106.5 million during Q2 2025, and its lowest value of $71.2 million during Q1 2022.
  • Over the past 3 years, Arcus Biosciences' median Shares Outstanding (Diluted Average) value was $90.1 million (recorded in 2024), while the average stood at $87.7 million.
  • In the last 5 years, Arcus Biosciences' Shares Outstanding (Diluted Average) dropped by 2.70% in 2022 and then increased by 24.45% in 2024.
  • Arcus Biosciences' Shares Outstanding (Diluted Average) (Quarterly) stood at $74.0 million in 2021, then dropped by 2.70% to $72.0 million in 2022, then increased by 2.78% to $74.0 million in 2023, then increased by 21.76% to $90.1 million in 2024, then climbed by 16.52% to $106.5 million in 2025.
  • Its last three reported values are $106.5 million in Q3 2025, $106.5 million for Q2 2025, and $98.4 million during Q1 2025.